Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)

書誌事項

公開日
2011-01-20
権利情報
  • http://creativecommons.org/licenses/by-nc-nd/3.0/
DOI
  • 10.2337/dc10-1407
公開者
American Diabetes Association

この論文をさがす

説明

<jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>The optimal treatment of hyperglycemia in general surgical patients with type 2 diabetes mellitus is not known.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>This randomized multicenter trial compared the safety and efficacy of a basal-bolus insulin regimen with glargine once daily and glulisine before meals (n = 104) to sliding scale regular insulin (SSI) four times daily (n = 107) in patients with type 2 diabetes mellitus undergoing general surgery. Outcomes included differences in daily blood glucose (BG) and a composite of postoperative complications including wound infection, pneumonia, bacteremia, and respiratory and acute renal failure.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>The mean daily glucose concentration after the 1st day of basal-bolus insulin and SSI was 145 ± 32 mg/dL and 172 ± 47 mg/dL, respectively (P &lt; 0.01). Glucose readings &lt;140 mg/dL were recorded in 55% of patients in basal-bolus and 31% in the SSI group (P &lt; 0.001). There were reductions with basal-bolus as compared with SSI in the composite outcome [24.3 and 8.6%; odds ratio 3.39 (95% CI 1.50–7.65); P = 0.003]. Glucose &lt;70 mg/dL was reported in 23.1% of patients in the basal-bolus group and 4.7% in the SSI group (P &lt; 0.001), but there were no significant differences in the frequency of BG &lt;40 mg/dL between groups (P = 0.057).</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>Basal-bolus treatment with glargine once daily plus glulisine before meals improved glycemic control and reduced hospital complications compared with SSI in general surgery patients. Our study indicates that a basal-bolus insulin regimen is preferred over SSI in the hospital management of general surgery patients with type 2 diabetes.</jats:p> </jats:sec>

収録刊行物

  • Diabetes Care

    Diabetes Care 34 (2), 256-261, 2011-01-20

    American Diabetes Association

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ